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Abstract: Microvascular complications characterized by retinopathy, nephropathy, and 
neuropathy are highly prevalent among diabetics. Glycemic control has long been the mainstay 
for preventing progression of these complications; however, such control is not easily achieved. 
Currently, alternative adjunctive approaches to treating and preventing microvascular damage 
are being undertaken by targeting the molecular pathogenesis of diabetic complications. This 
review summarizes the speciﬁ  c pathogenic mechanisms of microvascular complications for 
which clinical therapies have been developed, including the polyol pathway, advanced glyca-
tion end products, protein kinase c, vascular epithelium growth factor, and the superoxide 
pathway. The review further focuses on therapies for these targets that are currently available 
or are undergoing late-stage clinical trials.
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Introduction
Diabetes is estimated to have affected 171 million people worldwide in 2006 and is 
projected to affect 366 million by 2030 (The World Health Organization 2007). It 
was the 5th leading cause of death in 2000, and diabetic microvascular complications 
account for a signiﬁ  cant portion of the morbidity and mortality (Roglic et al 2005). 
Diabetic retinopathy, nephropathy, and neuropathy are the leading causes of blindness, 
end-stage renal disease, and amputations in the US (American Diabetes Association 
2007). Although type 1 and type 2 diabetes originate from different pathogenetic causes, 
there is a signiﬁ  cant association between hyperglycemia and the diabetic microvascular 
complications in both type 1 and type 2 diabetes (The Diabetes Control and Complica-
tions Trial Research Group 1993; UK Prospective Diabetes Study (UKPDS) Group 
1998). In the past decade, large, long-term prospective trials involving treatment and 
control of hyperglycemia in type 1 and 2 diabetics have shown microvascular related 
morbidity can be signiﬁ  cantly reduced but not entirely prevented through long-term 
glycemic and blood pressure control (The Diabetes Control and Complications Trial 
Research Group 1993; UK Prospective Diabetes Study (UKPDS) Group. 1998). Newer 
strategies to ameliorate or prevent microvascular complications involve a molecular 
understanding of diabetic complications.
Overview
The pathologic mechanisms underlying the susceptibility of retinal capillary endo-
thelial, renal glomeruli mesangial, and neural tissues to chronic hyperglycemia has 
been studied over the past century. With the 1966 discovery of the polyol pathway, a 
number of pathogenic mechanisms have been described including advanced glycation Vascular Health and Risk Management 2007:3(6) 824
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end products (AGEPs) , protein kinase C (PKC-β), the 
hexosamine pathway, and the unifying mechanism of superox-
ide production (Brownlee 2005). The activity of inﬂ  ammatory 
and angionenic regulating cytokines, such as nuclear factor 
(NF)-κB, tumor growth factor (TGF)-β, vascular endothelial 
growth factor (VEGF), connective tissue growth factor, and 
platelet derived growth factor, within the these mechanisms 
are well described. Ultimately, reactive oxygen species (ROS) 
are the end products of these various pathways.
With increasing understanding of diabetic pathophysiol-
ogy, the number of potential therapeutic targets for diabetic 
complications has multiplied as well. Within these targets 
lies the possibility of independently improving microvascular 
outcomes in addition to enhancing glycemic and blood pres-
sure control. While all aspects of diabetic pathophysiology are 
being targeted in experimental studies, the polyol pathway, 
AGEs, PKC-β, VEGF, and ROS have promising therapies 
developed against them that are now being clinically tested 
or are already approved for use. The following is a review of 
the clinical data supporting these emerging therapies.
Aldose reductase inhibitors 
and the polyol pathway
The polyol pathway reduces toxic aldehydes generated by 
ROS to inactive alcohols (Figure 1) (Brownlee 2001; Sheetz 
and King 2002). Aldose reductase (AR), via the consumption 
of NADPH, is responsible for the initial and rate-limiting step 
in the process. Glucose can be reduced to sorbitol, and eventu-
ally fructose, through this pathway, but AR has a low afﬁ  nity 
for glucose at normal concentrations. Elevated intracellular 
glucose can increase AR activity, resulting in signiﬁ  cantly 
decreased NADPH. NADPH is also required for glutathione 
reductase activity, which reduces glutathione (GSH)–a major 
mechanism for reducing intracellular oxidative stress (Lee and 
Chung 1999). Decreased NADPH and resulting decreased 
GSH reductase activity ultimately increases oxidative stress 
and activates pathways that increase cellular damage.
Aldose reductase inhibition (ARI) is ostensibly an ideal 
target for reducing the deleterious effects associated with polyol 
pathway activation. However, clinical trials with ARIs have 
shown lack of efﬁ  cacy or adverse effects. In the 1980’s, sorbinil 
became the ﬁ  rst ARI to undergo clinical trials after promising 
preclinical results. Results from several studies on neuropathy 
were mixed, but the majority suggested a lack of signiﬁ  cant 
effects (Jaspan et al 1986; Martyn et al 1987; Guy et al 1988; 
Sorbinil Retinopathy Trial Research Group 1993). Sorbinil was 
evaluated for treating retinopathy and nephropathy in the early 
1990’s but again showed a lack of efﬁ  cacy (Sorbinil Retinopathy 
Trial Research Group 1990; Sorbinil Retinopathy Trial Research 
Group 1993). Hypersensitivity reactions, occurring at increased 
doses, further limited the agent’s effectiveness.
Subsequent clinical evaluation of ARIs such as tolrestat 
or lidorestat were halted due to toxicities before their efﬁ  cacy 
could be deﬁ  nitively evaluated (Foppiano and Lombardo 1997). 
Others such as ponalrestat and zopolrestat were ineffective 
despite having more favorable side effect proﬁ  les (Sundkvist 
et al 1992). Zenarestat improved nerve conduction velocity 
and nerve morphology in a rigorous, year-long randomized, 
placebo-controlled trial (Greene et al 1999). However, further 
Phase 3 studies were eventually halted due to signiﬁ  cant creati-
nine elevations in study participants (Brown et al 2004).
Epalrestat was the ﬁ  rst successful ARI to be developed 
and was approved for use in Japan in 1992 for treatment of 
diabetic peripheral neuropathy. Randomized, double blinded, 
placebo-controlled trials of 12 and 24 weeks in diabetics 
with mild neuropathy suggested improved nerve conduc-
tion, vibration thresholds, and symptoms (Goto et al 1995: 
Uchida et al 1995). Improvement in peripheral neuropathy 
and minimal side effects were observed in a prospective 
observational study of more than 5,000 diabetics treated over 
3–12 months (Hotta et al 1996). Smaller long-term studies 
have also suggested the utility of epalrestat in ameliorating 
autonomic neuropathies related to cardiac function and gas-
tric and esophageal motility (Ikeda et al 1999; Nakayama 
et al 2001; Okamoto et al 2003; Kinekawa et al 2005). 
Epalrestat’s effects on nephropathy were evaluated via a 
placebo-controlled, randomized trial over 5 years. Thirty-
ﬁ  ve type 2 diabetics with baseline microalbuminuria were 
studied, and microalbuminuria was found to be unchanged in 
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Figure 1 Aldose reductase and the polyol pathway. Aldose reductase reduces aldehydes 
generated by ROS to inactive alcohols, and glucose is converted to sorbitol, using 
NADPH as a co-factor. For cells in which aldose reductase activity is sufﬁ  cient to 
deplete reduced GSH, oxidative stress is augmented. Sorbitol dehydrogenase (SDH) 
oxidizes sorbitol to fructose using NAD+ as a co-factor (Brownlee 2001) (Adapted 
by permission from Macmillan Publishers Ltd: Nature, Vol. 414, 2001).Vascular Health and Risk Management 2007:3(6) 825
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the treatment group, but signiﬁ  cantly increased in the placebo 
arm suggesting a beneﬁ  t in treating nephropathy (Iso et al 
2001). Recently, a 3-year randomized controlled trial involv-
ing 594 diabetics with mild to moderate neuropathy again 
showed that epalrestat was effective in improving median 
nerve conduction, vibration perception threshold, and symp-
toms without severe adverse effects (Hotta et al 2006). The 
study also showed a statistical difference in improvement and 
progression of retinopathy, although not microalbuminuria, 
between control and treatment groups. Cardiac autonomic 
effects were positive but not signiﬁ  cant.
Two new ARIs, fidarestat and ranirestat, have more 
recently been evaluated in safety and efﬁ  cacy studies in a 
randomized, double-blinded, placebo-controlled trial in the 
US and Japan in which 279 diabetics were studied (Hotta et al 
2001). Improvement in peripheral neuropathy, as evaluated 
by electrophysiological nerve studies and symptom reports, 
was statistically signiﬁ  cant compared to placebo with no dif-
ference in adverse effects between study and placebo groups. 
No data were reported regarding retinopathy or nephropathy. 
In 2004, Phase 2 trials were halted despite the positive results 
due to corporate restructuring of the trial sponsor. Whether 
evaluation of ﬁ  darestat will be resumed is unclear.
Ranirestat effectively penetrates peripheral nerves and has 
shown encouraging effects on peripheral neuropathy at both 5 
mg and 20 mg doses in a 12-week, double-blinded, placebo-
controlled trial (Bril and Buchanan 2004). A 48-week extension 
trial involving 86 of the participants continued the evaluation 
of nerve conduction studies, vibration perception thresholds, 
and neuropathic symptoms as assessed by the Toronto clinical 
neuropathy score (Bril and Buchanan 2006). The placebo arm 
participants were given low-dose ranirestat (5 mg) and the other 
treatment groups continued with their prior doses of 5 and 20 
mg. Further declines in nerve conduction were prevented and 
a statistically signiﬁ  cant improvement was observed in nerve 
conduction and symptoms by the study’s end. Although the 
extension was not sufﬁ  ciently powered or placebo controlled, 
the results are encouraging and must be validated in future trials. 
Phase 3 trials for ranirestat were completed in the US in Decem-
ber 2006, and publication of results are currently pending.
Inhibitors of AGEPs
AGEPs are a heterogeneous group of modiﬁ  ed proteins, 
lipids, and nucleic acids implicated in the aging process 
and diabetes. In intracellular hyperglycemia, these prod-
ucts are formed primarily through nonenzymatic reactions 
(Maillard reactions) between amino groups and glucose or 
highly reactive glucose derivatives known as dicarbonyls 
(Figure 2) (Brownlee 2001). Hyperglycemia may also drive 
AGEP formation through polyol pathway-derived intermedi-
ates and oxidative stress (Hamada et al 1996). AGEPs alter 
intracellular and extracellular proteins and their functions 
(Brownlee 2001; Goldin et al 2006; Huebschmann et al 
2006). Receptors for AGEPs (RAGE) may also bind AGEPs 
causing the NF-κB-mediated activation of various cytokines, 
pro-coagualtory and pro-inﬂ  ammatory factors, and increased 
vascular permeability (Brownlee 2001; Goldin et al 2006; 
Huebschmann et al 2006).
Studies in diabetic populations show AGEPs correlate 
with the development and severity of retinopathy, neuropa-
thy, and nephropathy as well as macrovascular complications 
(Monnier et al 2005). RAGE also exists in a soluble state 
(sRAGE) within the circulation and is thought to clear AGEP 
from the circulation, thereby preventing the binding of cel-
lular targets (Katakami et al 2005). Type 2 diabetics have 
lower sRAGE levels compared to nondiabetics, suggesting 
a downregulation of sRAGE in hyperglycemia. Strategies to 
prevent AGEP effects, aside from glycemic control, include 
decreasing exogenous AGEP intake, inhibiting AGEP for-
mation, disrupting AGEP cross-links, enhancing removal of 
AGEPs, and reducing oxidative stress.
Approximately 10% of exogenous AGEPs and their 
precursors consumed through diet are absorbed through 
the intestinal epithelium (Goldberg et al 2004). Foods with 
high AGEP content include meat, meat substitutes, high-fat 
foods, and foods cooked for prolonged periods or cooked 
at high temperatures (broiling, roasting, or frying). Con-
versely, fruits, vegetables, complex carbohydrates, lower 
temperature cooking methods, shorter cooking duration, 
or methods employing higher water contents (ie, boiling) 
are associated with lower AGEP levels. Clinical studies in 
human diabetics are limited but do show increased circulat-
ing AGEP levels and markers of inﬂ  ammation associated 
with increased dietary intake (Goldberg et al 2004; Uribarri 
et al 2005). Exogenous AGEPs are also increased through 
tobacco smoking – smoking cessation reduces exogenous 
AGEPs (Cerami et al 1997).
Aminoguanidine, the ﬁ  rst targeted AGEP therapy, is a 
hydrazine derivative that prevents AGEP formation by binding 
reactive carbonyl intermediates (Thornalley 2003). Aminogua-
nidine’s effects on nephropathy and retinopathy in 690 type 1 
diabetics were evaluated in a randomized, double-blinded, pla-
cebo-controlled trial. Progression of glomerular ﬁ  ltration rate 
(GFR) decline, proteinuria, and retinopathy was signiﬁ  cantly 
improved, although 3 patients given high-dose aminoguanidine 
developed glomerulonephritis (Bolton et al 2004). A similar Vascular Health and Risk Management 2007:3(6) 826
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follow-up study was halted due to safety concerns and an 
apparent lack of efﬁ  cacy (Freedman et al 1999).
A newer agent, alagebrium chloride (ALT-711) cleaves 
AGEP and protein cross-links thereby facilitating AGEP 
clearance. Two clinical trials with mixed diabetic and non-
diabetic populations with atherosclerosis and heart failure 
reveals that Alt-711 can improve vascular and left ventricular 
compliance with adverse effects similar to placebo (Kass et al 
2001; Little et al 2005). In animal studies, ALT-711 was ben-
eﬁ  cial in treating diabetic renal complications (Forbes et al 
2003); however, no clinical studies to date have evaluated 
its effects on the microvascular system.
The effects of two B vitamins on AGEPs have also been 
clinically studied in humans. The highly bioavailable thia-
mine derivative, benfotiamine, was studied in 13 diabetics 
who consumed an AGEP-rich meal (Stirban et al 2006). 
Postprandial AGEP levels and markers of endothelial dys-
function were signiﬁ  cantly decreased after bentofamine was 
administered for 3 days. Benfotiamine has also been shown 
to improve the symptoms of diabetic polyneuropathy in 2 
studies in which AGEPs were not measured (Winkler et al 
1999; Haupt et al 2005). A combination of bentofamine and 
pyroxidine (as well as vitamin B12) have been studied in 
both diabetic and alcoholic neuropathy and both improved 
symptoms and nerve conduction velocity, although AGEP 
effects were not speciﬁ  cally evaluated (Stracke et al 1996; 
Woelk et al 1998). Pyridoxamine is proposed to improve 
AGEP-related complications through dicarbonyl clearance, 
prevention of oxidative damage, and prevention of AGEP 
formation (Voziyan and Hudson 2005). A Phase II random-
ized, double-blinded, placebo-controlled trial with 128 
diabetics with nephropathy, most of whom were on ACE 
or ARB therapy, revealed signiﬁ  cantly decreased rates of 
creatinine elevations and albuminuria that was especially 
marked among those with more advance disease (Williams 
et al 2003). Adverse events did not include neurotoxicities 
and were similar to placebo (Williams 2006).
In additional studies, AGEPs have been evaluated in 
diabetes, hypertension, and lipid modulation. Epalrestat has 
been shown to reduce serum AGEPs in diabetics after 2–3 
months of use (Nakamura et al 2003; Hamada et al 2000). 
AGEP modulation by metformin was compared to insulin, 
sulfonyureas, or insulin plus sulfonyureas in type 2 diabet-
ics with similar glycemic control and no renal impairment 
(Beisswenger et al 1999). Metformin was superior in reduc-
ing reactive dicarbonyl precursors compared to insulin or 
sulfonyureas in any combination independent of glycemic 
control. In type 1 diabetics, perindopril has been shown to 
increase soluble RAGE, an endogenous RAGE clearance 
mechanism, and decrease low molecular weight AGEPs over 
2 years when compared to nifedipine (Forbes et al 2005). 
In contrast, the ARB, irbesartan, did not affect AGEPs in a 
separate clinical evaluation (Persson et al 2006). Simvastatin 
treatment and adherence to an American Heart Association 
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Figure 2 Mechanisms by which intracellular production of advanced glycation end-product (AGE) precursors damages vascular cells. Covalent modiﬁ  cation of intracellular 
proteins by dicarbonyl AGE precursors alters several cellular functions. Modiﬁ  cation of extracellular matrix proteins causes abnormal interactions with other matrix proteins 
and with integrins. Modiﬁ  cation of plasma proteins by AGE precursors creates ligands that bind to AGE receptors, inducing changes in gene expression in endothelial cells, 
mesangial cells and macrophages (Brownlee 2001) (Adapted by permission from Macmillan Publishers Ltd: Nature, Vol. 414, 2001).Vascular Health and Risk Management 2007:3(6) 827
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diet for 4 months also has been shown to decrease cellular 
RAGE in carotid plaques of type 2 diabetics independent 
of glycemic control versus dietary modifications alone 
(Cuccurullo et al 2006). None of these studies speciﬁ  cally 
evaluated microvascular indices and further clinical trials are 
needed to conﬁ  rm potential outcome beneﬁ  ts.
Diacylglycerol PKC inhibition
The PKC family consists of a group of 12 seronine/
threonine kinases involved in intracellular signaling related 
to a variety of vascular, cardiac, immunologic, and other 
systemic functions (Mellor and Parker 1998; Sheetz and 
King 2002). Diacylglycerol (DAG) is an upstream activator 
in the majority of PKC isoforms (Koya and King 1998; 
Inoguchi et al 1992). De novo DAG formation increases 
with elevated intracellular glucose with a resultant increase 
of primarily PKC-β1/2 and PKC-δ isoform activity (Fig-
ure 3) (Koya and King 1998). PKC may also be activated 
by growth factors, and hyperglycemia-induced superoxide 
and AGE formation (Koya and King 1998; Sheetz and 
King 2002).
PKC-β1 and 2 are chiefly responsible the deleteri-
ous effects on retinal, neural, and renal tissues (Inoguchi 
et al 1992; Shiba et al 1993; Craven et al 1990). These 
isoforms impair retinal and renal blood ﬂ  ow, and increase 
capillary leakage (Feke et al 1994). PKC-induced increased 
extracellular matrix production and upregulation of vari-
ous inﬂ  ammatory cytokines further damage the macro and 
microvascular systems (Craven et al 1997).
PKC412, while not exclusively a PKC inhibitor, was the 
ﬁ  rst PKC inhibitory agent to undergo clinical evaluation 
in a randomized, double-blinded, placebo-controlled trial 
(Campochiaro et al 2004). While effective in treating dia-
betic macular edema, further studies of PCK412 were aban-
doned due to hepatotoxicity. Ruboxistaurin is a selective 
PKC-β inhibitor that has been shown to improve retinal 
circulation parameters and decrease diabetic macular edema 
retinal leakage without signiﬁ  cant adverse effects (Strom 
et al 2005; Aiello et al 2006a). In clinical trials to control 
progression of retinopathy, ruboxistaurin’s results are 
mixed. In a randomized, double blinded placebo-controlled 
study (PKC-DRS) of 192 diabetics with moderate to severe 
nonproliferative retinopathy treated with various doses of 
ruboxistaurin, retinopathic progression did not decrease 
over a period of up to 4 years, although moderate vision 
loss was signiﬁ  cantly decreased in the high-dose (32 mg) 
treatment group (The PKC-DRS Study Group 2005). In a 
subgroup with macular edema, additional vision loss was 
prevented in the high-dose treatment group versus placebo, 
and adverse effects were similar to placebo. In the fol-
low up study (PKC-DRS 2), 685 diabetics with macular 
edema for 36 months were assessed for the prevention of 
sustained vision loss as the primary end point. As in the 
prior studies, ruboxistaurin (32 mg) prevented progres-
sion of sustained moderate visual loss with a relative risk 
reduction of 45% versus placebo (Aiello et al 2006b). Also, 
signiﬁ  cant prevention of macular edema progression and a 
decreased need for initial photocoagulation was observed 
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Figure 3 Consequences of hyperglycemia-induced activation of protein kinase C (PKC). Hyperglycemia increases diacylglycerol (DAG) content, which activates PKC, primarily 
the b- and d-isoforms. Activation of PKC has a number of pathogenic consequences by affecting expression of endothelial nitric oxide synthetase (eNOS), endothelin-1 
(ET-1), VEGF, TGF-β, and plasminogen activator inhibitor-1 (PAI-1), and by activating NF-κB and NAD(P)H oxidases (Brownlee 2001) (Adapted by permission from Macmillan 
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in the treatment group; although, retinopathic progression 
was not affected.
A recent randomized, double-blinded, placebo-controlled 
trial of 123 diabetics with albuminuria who were taking 
ACE or ARB therapy indicated that ruboxistaurin reduces 
albuminuria:creatinine ratios versus placebo (Tuttle et al 
2005). GFR was also preserved relative to baseline in the 
treatment group, but this study was not of sufﬁ  cient statisti-
cal power to compare GFR trends between treatment and 
placebo groups. The effect of ruboxistaurin on diabetic 
peripheral neuropathy (DPN) has also been evaluated in 
a 1-year randomized, double-blinded, placebo-controlled 
trial of 205 diabetics (Vinik et al 2005). While participants 
with symptomatic DPN showed signiﬁ  cant improvement 
of symptoms, only a subgroup with less severe baseline 
features showed signiﬁ  cant improvement of their vibration 
detection threshold and symptoms. Ruboxustaurin is cur-
rently pending FDA approval for the treatment of diabetic 
macular edema.
VEGF inhibitors
VEGF is a glycoprotein whose production is increased in 
hyperglycemia, primarily through the PKC pathway. VEGF 
mediates its effects on the retina through the receptor tyrosine 
kinases VEGFR-1 and VEGFR-2 (Shen et al 1993; Ferrara 
2004). In turn, angiogenesis is stimulated and capillary per-
meability and leakage are increased (Shen et al 1993; Dvorak 
et al 1995; Ferrara 2004). Vitreous VEGF levels reﬂ  ect the 
severity of neovascularization in diabetic retinopathy and 
decline with photocoagulation (Aiello et al 1994; Funatsu 
et al 2006). Experimental data suggests there are similar 
elevations in renal tissue although the pathogenesis is less 
well established (Hohenstein et al 2006).
Systemic therapies against VEGF are impractical as 
VEGF is vital in processes such as angiogenesis in the myo-
cardium and wound healing (van Wijngaarden et al 2005). 
Intraocular injections of VEGF inhibitors represent a method 
of targeted therapy that would avoid the adverse systemic 
effects. Three drugs are currently being studied in clinical 
settings: pegaptanib, ranizumab, and bevacizumab.
Pegaptanib sodium is an anti-VEGF aptamer which binds 
VEGF and prevents it from interacting with its receptors 
(Gragoudas et al 2004). Two concurrent, prospective, double-
blinded, randomized, sham-controlled trials in patients with 
non-diabetic age related macular edema suggest that have 
intraocular injections at 6-week intervals over the course 
of 48 weeks slow visual loss (Gragoudas et al 2004). In 
diabetics, a similarly designed study over 36 weeks showed 
that pegaptanib improved visual acuity outcomes, preserved 
central retinal thickness, and required less photocoagulation 
therapy in 172 participants with baseline diabetic macular 
edema (Cunningham Jr et al 2005). Adverse events were 
similar among treatment and control groups, although 8% of 
all participants experienced a severe adverse event, and 16 of 
the participants also had baseline retinal neovascularization 
and were subsequently followed for neovascular progression 
in a separate study (Adamis et al 2006). Pegaptanib led to 
regression in 62% of treated eyes versus 0% of the control 
group.
Ranizumab and bevacizumab are recombinant human-
ized monoclonal antibody fragments and full-length 
antibodies, respectively (Steinbrook 2006). Both agents 
are derived from the same mouse monoclonal antibody 
precursor and show high afﬁ  nity for VEGF, neutralizing 
its effects by binding to VEGF and preventing VEGFR 
interaction. Bevacizumab was originally designed for intra-
venous injection as a chemotherapeutic against metastatic 
colorectal cancer, but it has been adapted for off-label use 
as an intraocular injection similar to ranizumab (Hurwitz 
et al 2004; Rosenfeld 2006a). Several case series and studies 
have also suggested bevacizumab to be safe and effective 
in decreasing retinal neovascularization and macular edema 
in diabetics (Avery et al 2006; Haritoglou et al 2006; Jorge 
et al 2006; Mason et al 2006; Oshima et al 2006; Spaide 
and Fisher 2006). Two large prospective randomized stud-
ies have recently been completed in which ranizumab was 
assessed for treatment of nondiabetic, age-related macular 
edema (Brown and Kaiser 2006; Rosenfeld et al 2006b). 
The studies show ranizumab to be superior in improving 
visual acuity and regression of neovascularization with a 
low incidence of serious adverse events over 1 year versus 
either sham injection or verteporﬁ  n photodynamic therapy. 
In a 2-year pilot study in 10 diabetics with clinically sig-
niﬁ  cant macular edema, similar ﬁ  ndings of improved visual 
acuity and central retinal thickness were observed, and 
safety was not a concern (Chun et al 2006).
The new VEGF inhibitors show promise in targeting 
diabetic retinopathy, but are cost-prohibitive (Steinbrook 
2006), and no trials have indicated that one is superior to 
the others. Additionally, systemic effects have been noted 
in the intraocular preparations (Jorge et al 2006). Bevaci-
zumab, in particular, has been investigated in this regard 
due to its longer half life (Steinbrook 2006). Finally, the 
question of whether prolonged inhibition of VEGF may 
actually further retinal deterioration remains to be answered 
(Csaky 2003).Vascular Health and Risk Management 2007:3(6) 829
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Antioxidant therapy and ROS
ROS are end products of pathogenic pathways as well as the 
hexosamine pathway and they are the cause of diabetic micro-
vascular injury. ROS have long been targeted in therapeutic 
trials for diabetic microvascular complications. A detailed 
review of antioxidants is beyond the scope of this paper, but 
clinical studies of diabetics who were supplemented with 
traditional antioxidants (vitamins C and E) indicated that 
markers of oxidative stress were alleviated microvascular 
complications were not prevented or improved (Lonn et al 
2002; Scott and King 2004; Liu et al 2006).
Our understanding of the roles of oxygen free radicals 
in diabetic complications has recently evolved with the 
description of the super oxide pathway (Brownlee 2001). In 
hyperglycemia, experimental endothelial cells have increased 
ﬂ  ux of glucose through glycolysis, pyruvate decarboxylation, 
and the citric acid cycle resulting in mitochondrial electron 
transport chain overload (Nishikawa et al 2000). In turn, 
overloaded mitochondria produce excessive superoxide 
anions which ultimately lead to decreases in nitric oxide, 
DNA damage, AGE formation, and activation of the polyol, 
PKC, and hexosamine pathways as well as activation of 
poly (ADP-ribose) polymerase (Figure 4) (Du et al 2000; 
Nishikawa et al 2000; Brownlee 2001).
The realization that ROS both contribute to induc-
tion of major pathways of diabetic complications and 
comprise the pathway’s end products may explain why 
traditional antioxidants have failed. Vitamin E and others 
antioxidants act primarily to non-enzymatically scavenge 
certain end-product ROS thereby limiting their effects to 
only a portion of the damaging end-product (Du et al 2000). 
Currently used agents for diabetic microvascular control, 
including thiazolinediones, angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers, and statins are 
believed to derive some of their beneﬁ  t from modulat-
ing superoxides (Ceriello 2003). To improve the effect 
of antioxidant therapy, compounds are being studied that 
speciﬁ  cally act against superoxide and prevent induction 
of the various pathogenic mechanisms.
α-lipoic acid is one such compound that has received the 
most attention in clinical trials, which indicated that it can 
reduce markers of oxidation in poorly controlled diabetics 
and in patients with metabolic syndrome (Borcea et al 1999; 
Sola et al 2005). A meta analysis of 4 randomized, double-
blinded, placebo-controlled, 3-week trials of 1,258 diabetics 
showed that 600 mg of α-lipoic acid signiﬁ  cantly improved 
measures of DPN (Ziegler et al 2004). More recently, a 
randomized, double-blinded, placebo-controlled trial of 
182 type 1 and 2 diabetics were treated with α-lipoic acid 
(600–1800 mg) over 5 weeks was conducted to evaluated the 
effects on DPN (Ziegler et al 2006). All treated groups had 
signiﬁ  cantly improved pain and neuropathy as assessed by a 
total symptom score (TSS), a neuropathy impairment score, 
and a neuropathy and symptoms and change score (NCS). 
Nerve conduction studies and symptoms of numbness and 
parathesia did not signiﬁ  cantly improve and dose-related 
nausea, vomiting, and vertigo were noted with treatment. No 
clinical data exist regarding treatment of diabetic retinopathy, 
although at least one study assessed its effects on nephropa-
thy. A prospective non-randomized, open, placebo-controlled 
study of 84 type 1 and 2 diabetics was conducted to evalu-
ate the effect of α-lipoic acid over 18 months (Morcos et al 
2001). Urinary albuminuria was increased in the placebo 
group but unchanged in the treatment group.
Conclusion
Greater understanding of diabetic pathophysiology is yielding 
promising results by guiding the development of these new 
targeted therapies. Agents such as epalrestat, ruboxistaurin, 
ranizumab, and α-lipoic acid have been well studied and are 
now or soon to be available in certain countries. The newer 
ARI and AGE therapies require further large-scale trials 
to verify their efﬁ  cacy, but the initial results are encourag-
ing. While not covered here, other notable new therapies 
that do not necessarily target speciﬁ  c diabetic pathophysi-
ologic mechanisms such as glycosaminoglycan sulodexide 
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Figure 4 Potential mechanism by which hyperglycemia-induced mitochondrial 
superoxide overproduction activates four pathways of hyperglycemic damage.  Excess 
superoxide partially inhibits the glycolytic enzyme GAPDH, thereby diverting upstream 
metabolites from glycolysis into pathways of glucose overutilization. This results in 
increased ﬂ  ux of dihydroxyacetone phosphate (DHAP) to DAG, an activator of PKC, 
and of triose phosphates to methylglyoxal, the main intracellular AGE precursor. 
Increased ﬂ  ux of fructose-6-phosphate to UDP-N-acetylglucosamine increases modi-
ﬁ  cation of proteins by O-linked N-acetylglucosamine (GlcNAc) and increased glucose 
ﬂ  ux through the polyol pathway consumes NADPH and depletes GSH (Brownlee 2001) 
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for nephropathy, intraocular steroids for retinopathy, or 
monochromatic near-infrared treatment for neuropathy are 
also showing beneﬁ  t (Solini et al 1997; Gambaro et al 2002; 
Simpson et al 2004; Sutter et al 2004; Achour et al 2005; 
Clifft et al 2005; Gillies et al 2006). These new therapies are 
likely to represent a signiﬁ  cant change in the management of 
diabetic retinopathy, nephropathy, and neuropathy beyond 
glycemic and blood pressure control.
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